GlassScriptPhysician profile
Alvaro Rios
NPI 1821074436
$6,973.37
in general payments reported to CMS, 2019-2025
42 companies · $817 in 2025
The $817 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,761 · 2020: $304 · 2021: $1,135 · 2022: $1,252 · 2023: $1,026 · 2024: $678 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.79 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $914.74 | 2019 | |
| Pfizer INC. | $660.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $560.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $499.21 | 2021-2025 | Verquvo, Capvaxive |
| Astellas Pharma US INC | $454.98 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $383.37 | 2021-2025 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $361.91 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $347.85 | 2019-2023 | Xarelto |
| Amgen INC. | $328.21 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $322.36 | 2019-2025 | Jot Dx, Diamondback Peripheral, Mitraclip |
| Heartflow, INC. | $287.94 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $219.31 | 2019-2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $172.03 | 2020-2024 | Farxiga, Andexxa |
| Kiniksa Pharmaceuticals, LTD. | $139.81 | 2022-2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.20 | 2019-2025 | Jardiance |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $112.73 | 2020-2022 | |
| Cardiovascular Systems INC. | $93.78 | 2021-2023 | Diamondback Coronary |
| Amarin Pharma, INC. | $93.66 | 2019-2021 | |
| Philips North America LLC | $83.83 | 2019-2025 | (Ck4) Mcot, Ambulatory Monitoring & Diagnostics Undivided, (Ck7) Extended Holter |
| Atricure, INC. | $77.56 | 2022-2023 | |
| Glaxosmithkline, LLC. | $62.86 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $62.18 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $61.74 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $58.79 | 2025 | |
| Biotronik INC. | $53.88 | 2019 | |
| Scpharmaceuticals INC. | $48.04 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $44.89 | 2025 | Onpattro, Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $40.56 | 2024 | Arcalyst |
| Stryker Corporation | $40.27 | 2020 | |
| Angiodynamics, INC. | $39.55 | 2021-2022 | |
| Boston Scientific Corporation | $36.46 | 2019-2022 | |
| Novo Nordisk INC | $35.62 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $29.13 | 2023 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.02 | 2023 | Lifevest |
| Ethicon US, LLC | $16.49 | 2025 | Vistaseal |
| Althera Pharmaceuticals LLC | $14.68 | 2021 | |
| Kestra Medical Technology Services, INC. | $14.40 | 2025 | Assure Wcd |
| Medtronic, INC. | $13.04 | 2023 | Micra |
| Cashflow Solutions, LLC | $12.71 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Preventice Services, LLC | $12.06 | 2021 | |
| Exelixis INC. | $11.68 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvaro Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.